SCH-48461

ID: ALA23541

Max Phase: Preclinical

Molecular Formula: C26H27NO3

Molecular Weight: 401.51

Molecule Type: Small molecule

Associated Items:

Representations

Synonyms (2): SCH-47949 | SCH-48461
Synonyms from Alternative Forms(2):

    Canonical SMILES:  COc1ccc([C@@H]2[C@@H](CCCc3ccccc3)C(=O)N2c2ccc(OC)cc2)cc1

    Standard InChI:  InChI=1S/C26H27NO3/c1-29-22-15-11-20(12-16-22)25-24(10-6-9-19-7-4-3-5-8-19)26(28)27(25)21-13-17-23(30-2)18-14-21/h3-5,7-8,11-18,24-25H,6,9-10H2,1-2H3/t24-,25-/m1/s1

    Standard InChI Key:  IMNTVVOUWFPRSB-JWQCQUIFSA-N

    Associated Targets(Human)

    Acyl coenzyme A:cholesterol acyltransferase 1 857 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    HepG2 196354 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Caco-2 12174 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Associated Targets(non-human)

    Cricetinae gen. sp. 3197 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Acyl coenzyme A:cholesterol acyltransferase 1 2344 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Rattus norvegicus 775804 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Sterol O-acyltransferase 1 43 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Monkey 844 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Canis familiaris 36305 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Hamster 598 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Rhesus monkey 3147 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Molecule Features

    Natural Product: NoOral: NoChemical Probe: NoParenteral: No
    Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
    Chirality: NoAvailability: NoProdrug: No

    Drug Indications

    MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

    Mechanisms of Action

    Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

    Properties

    Molecular Weight: 401.51Molecular Weight (Monoisotopic): 401.1991AlogP: 5.43#Rotatable Bonds: 8
    Polar Surface Area: 38.77Molecular Species: NEUTRALHBA: 3HBD: 0
    #RO5 Violations: 1HBA (Lipinski): 4HBD (Lipinski): 0#RO5 Violations (Lipinski): 1
    CX Acidic pKa: CX Basic pKa: CX LogP: 5.49CX LogD: 5.49
    Aromatic Rings: 3Heavy Atoms: 30QED Weighted: 0.47Np Likeness Score: -0.02

    References

    1. Dugar S, Yumibe N, Clader JW, Vizziano M, Huie K, Van Heek M, Compton DS, Davis HR.  (1996)  Metabolism and structure activity data based drug design: discovery of () SCH 53079 an analog of the potent cholesterol absorption inhibitor () SCH 48461,  (11): [10.1016/0960-894X(96)00214-4]
    2. Dugar S, Yumibe N, Clader JW, Vizziano M, Huie K, Van Heek M, Compton DS, Davis HR.  (1996)  Metabolism and structure activity data based drug design: discovery of () SCH 53079 an analog of the potent cholesterol absorption inhibitor () SCH 48461,  (11): [10.1016/0960-894X(96)00214-4]
    3. Burnett DA, Caplen MA, Davis HR, Burrier RE, Clader JW..  (1994)  2-Azetidinones as inhibitors of cholesterol absorption.,  37  (12): [PMID:8021912] [10.1021/jm00038a001]
    4. Burnett DA, Caplen MA, Davis HR, Burrier RE, Clader JW..  (1994)  2-Azetidinones as inhibitors of cholesterol absorption.,  37  (12): [PMID:8021912] [10.1021/jm00038a001]
    5. Burnett DA, Caplen MA, Davis HR, Burrier RE, Clader JW..  (1994)  2-Azetidinones as inhibitors of cholesterol absorption.,  37  (12): [PMID:8021912] [10.1021/jm00038a001]
    6. McKittrick BA, Ma K, Dugar S, Clader JW, Davis H, Czarniecki M, McPhail AT.  (1996)  Stereoselective synthesis and biological activity of cis azetidinones as cholesterol absorption inhibitors,  (16): [10.1016/0960-894X(96)00347-2]
    7. Dugar S, Kirkup MP, Clader JW, Lin S, Rizvi R, Snow ME, Davis HR, McCombie SW.  (1995)  Gamma-lactams and related compounds as cholesterol absorption inhibitors: homologs of the beta-lactam cholesterol absorption inhibitor SCH 484611,  (24): [10.1016/0960-894X(95)00516-6]
    8. Dugar S, Kirkup MP, Clader JW, Lin S, Rizvi R, Snow ME, Davis HR, McCombie SW.  (1995)  Gamma-lactams and related compounds as cholesterol absorption inhibitors: homologs of the beta-lactam cholesterol absorption inhibitor SCH 484611,  (24): [10.1016/0960-894X(95)00516-6]
    9. Burnett DA, Caplen MA, Domalski MS, Browne ME, Davis HR, Clader JW..  (2002)  Synthesis of iodinated biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors.,  12  (3): [PMID:11814785] [10.1016/s0960-894x(01)00750-8]
    10. Vaccaro WD, Davis HR..  (1998)  Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: enhanced potency by modification of the sugar.,  (3): [PMID:9871676] [10.1016/s0960-894x(98)00008-0]
    11. Burnett DA, Caplen MA, Browne ME, Zhau H, Altmann SW, Davis HR, Clader JW..  (2002)  Synthesis of fluorescent biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors.,  12  (3): [PMID:11814786] [10.1016/s0960-894x(01)00752-1]
    12. Vaccaro WD, Sher R, Davis HR..  (1998)  Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors.,  (3): [PMID:9871677] [10.1016/s0960-894x(98)00009-2]
    13. Vaccaro WD, Sher R, Davis HR..  (1998)  Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors.,  (3): [PMID:9871677] [10.1016/s0960-894x(98)00009-2]
    14. Clader JW, Burnett DA, Caplen MA, Domalski MS, Dugar S, Vaccaro W, Sher R, Browne ME, Zhao H, Burrier RE, Salisbury B, Davis HR..  (1996)  2-Azetidinone cholesterol absorption inhibitors: structure-activity relationships on the heterocyclic nucleus.,  39  (19): [PMID:8809157] [10.1021/jm960405n]
    15. Vaccaro WD, Sher R, Davis HR..  (1998)  Sugar-substituted 2-azetidinones as cholesterol absorption inhibitors.,  (1): [PMID:9871624] [10.1016/s0960-894x(97)10185-8]
    16. Dugar S, Clader JW, Chan TM, Davis H..  (1995)  Substituted 2-azaspiro[5.3]nonan-1-ones as potent cholesterol absorption inhibitors: defining a binding conformation for SCH 48461.,  38  (25): [PMID:8523398] [10.1021/jm00025a002]
    17. Dugar S, Clader JW, Chan TM, Davis H..  (1995)  Substituted 2-azaspiro[5.3]nonan-1-ones as potent cholesterol absorption inhibitors: defining a binding conformation for SCH 48461.,  38  (25): [PMID:8523398] [10.1021/jm00025a002]
    18. McKittrick BA, Ma K, Huie K, Yumibe N, Davis H, Clader JW, Czarniecki M, McPhail AT..  (1998)  Synthesis of C3 heteroatom-substituted azetidinones that display potent cholesterol absorption inhibitory activity.,  41  (5): [PMID:9513603] [10.1021/jm970676d]
    19. Rosenblum SB, Huynh T, Afonso A, Davis HR, Yumibe N, Clader JW, Burnett DA..  (1998)  Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.,  41  (6): [PMID:9526571] [10.1021/jm970701f]
    20. Itzhak Y, Kalir A, Weissman BA, Cohen S..  (1981)  New analgesic drugs derived from phencyclidine.,  24  (5): [PMID:7241506] [10.1021/jm00137a004]
    21. Itzhak Y, Kalir A, Weissman BA, Cohen S..  (1981)  New analgesic drugs derived from phencyclidine.,  24  (5): [PMID:7241506] [10.1021/jm00137a004]
    22. Kvaernø L, Werder M, Hauser H, Carreira EM..  (2005)  Synthesis and in vitro evaluation of inhibitors of intestinal cholesterol absorption.,  48  (19): [PMID:16162006] [10.1021/jm050422p]
    23. Mehta PD, Sengar NP, Pathak AK..  (2010)  2-Azetidinone--a new profile of various pharmacological activities.,  45  (12): [PMID:20970895] [10.1016/j.ejmech.2010.09.035]

    Source